<DOC>
	<DOCNO>NCT00506662</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare insulin detemir daily NPH insulin daily measure blood sugar control age subject type 2 diabetes naive previous insulin therapy .</brief_summary>
	<brief_title>Comparison Insulin Detemir NPH Insulin Given Once Daily Ageing Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>Novo Nordisk decide discontinue trial possible recruit require number patient . The discontinuation base analysis significant delay recruitment patient likely negative impact validity trial .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Insulin naive Treatment oral antidiabetic drug ( OADs ) least 3 month achieve therapeutic target HbA1c 8 % 10.5 % Secondary diabetes , MODY ( Maturity Onset Diabetes Young ) Previous treatment insulin ( except shortterm treatment insulin intercurrent illness judge Investigator ) Proliferative retinopathy , maculopathy require treatment , Hypoglycaemia unawareness judge Investigator , recurrent major hypoglycaemia End stage liver disease ( increase liver enzymes 4 fold ) , end stage renal disease assess MDRD ( Modification Diet Renal Disease ) less 30 ml/min dialyse patient , acute heart failure , acute cardiovascular event cerebrovascular event le 6 month Acute disease poor prognosis History alcoholism , drug abuse , psychiatric disease personality disorder likely invalidate voluntary consent prevent good compliance trial protocol Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation ( patient score less 15 previous MMSE ( MiniMental State Examination ) last six month ) condition judge investigator Legal incapacity limit legal capacity ( patient guardianship curatorship ) Concomitant medication Alzheimers treatment ( Memantine , Anticholinesterasique treatment ) Participation another clinical trial le one month inclusion trial Illness require repeat hospitalisation Known suspect allergy insulin compositional component Anticipated change new use concomitant medication know interfere glucose metabolism , systemic corticotherapy 5 mg/day ( prednisone ) Any condition Investigator feel would interfere trial participation evaluation result Terminal illness</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>